| Literature DB >> 23927422 |
C Sehwan Park1, Hubert Rehrauer, Isabelle M Mansuy.
Abstract
BACKGROUND: Histone acetylation has been implicated in learning and memory in the brain, however, its function at the level of the genome and at individual genetic loci remains poorly investigated. This study examines a key acetylation mark, histone H4 lysine 5 acetylation (H4K5ac), genome-wide and its role in activity-dependent gene transcription in the adult mouse hippocampus following contextual fear conditioning.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23927422 PMCID: PMC3751108 DOI: 10.1186/1471-2164-14-539
Source DB: PubMed Journal: BMC Genomics ISSN: 1471-2164 Impact factor: 3.969
Figure 1Contextual fear memory and its association with H4K5ac in the hippocampus. (A) Scheme of the behavioral experiment. Mice were trained on contextual fear conditioning (CFC) on day 1 (FC Day 1), tested 24 hours later on day 2 (Test Day 2), or conditioned again immediately following the test (FC Day 2), and tested again 24 hours later on day 3 (Test Day 3). Hippocampi were collected either one hour following FC Day 1 or one hour following Test Day 3. (B) Fear memory was measured as the freezing response before and after the foot-shock (shock) on FC Day 1, after re-exposure to the context on day 2 (Test Day 2), and after re-exposure to the context on day 3 in fear-conditioned (FC; n = 12) and in non-fear-conditioned controls (Control; n = 11). (C) Quantitative analysis and representative immunoblots of H4K5ac levels in nuclear fractions from whole hippocampus in controls one hour after context on day 1 (Control, n = 4), one hour after CFC on day 1 (Day 1 After FC; n = 4), or one hour after the memory test on day 3 (Day 3 Test; n = 3). Samples derived for immunoblots were processed in parallel using actin for normalization and run on two different gels. Error bars indicate SEM. *p < 0.05, **p < 0.01, ***p < 0.001.
Figure 2Distribution of H4K5ac in the genome and its profile relative to the TSS. (A) Distribution of reads from H4K5ac with respect to intragenic regions including promoter, CDS (introns and exons) and intergenic regions in the hippocampus after CFC compared to (B) mock IgG-IP. Promoters were defined as 5 kb upstream of the TSS, the CDS as regions between the TSS and TTS, and intergenic as regions excluding gene bodies. Reads spanning the transcription start site that match both a promoter and transcript are counted twice, thus, leading to total reads greater than 100%. (C) Profile of reads for H4K5ac (red) and IgG-IP controls (green) across ± 5 kb relative to the TSS (left) and spanning the CDS as a percentage of reads averaged over all genes (right). (D) Distribution of reads for H4K5ac and (E) IgG-IP by genomic regions in the absence of CFC (Control). (F) Profile of reads for H4K5ac (red) or IgG-IP (green) in Control. Distribution profiles for H4K5ac after 2 days CFC (red) compared to (G) H4K12ac immediately after 1 CFC session (green) [4]. Window analyses were obtained using EpiChIP [48].
Figure 3Qualitative assessment of H4K5ac and gene expression. (A) Expressed genes in the adult mouse hippocampus 1 hour after CFC compared to naïve controls are ranked from the lowest (cyan) to the highest expressed (orange) into 10 equal bins (1801 genes). Genes ranked by expression are correlated to average coverage for H4K5ac in (B) FC and (C) control mice re-exposed to the context on day 3, or to (D) H4K12ac immediately after CFC on day 1; average read coverage ± 5 kb relative to the TSS. (E) Venn diagram of unique and overlapping genes identified by acetylation above the average across all genes: with an H4K5ac threshold of greater than 50 reads in promoter, and a threshold of greater than 10 reads in promoter for H4K12ac.
Figure 4H4K5ac enrichment in the promoter and CDS. (A) Genes acetylated for H4K5 after CFC are clustered based on acetylation profiles over ±2 kb relative to the TSS. Clusters 3 (green), 4 (blue), and 5 (violet) occur in promoter regions, cluster 1 (red) occurs in the CDS, and cluster 2 (yellow) is unenriched for H4K5ac. (B) Contribution of gene clusters with respect to levels of gene expression show higher contribution of clusters enriched for H4K5ac with higher expression. (C) Clustering of genes acetylated for H4K12ac after CFC generated clusters 2 (yellow) and 5 (violet) in the promoter region, clusters 1 (red) and 3 (green) in the CDS, and cluster 4 (blue) is unenriched for H4K12ac. (D) The contribution of clusters enriched for H4K12ac is also higher with higher gene expression levels. (E) Clustering of genes obtained from IgG-IP controls after CFC result in uniformly distributed clusters including clusters 1 (red), 3 (green), and 5 (blue) in the promoter region, and clusters 2 (yellow) and 4 (blue) in the CDS. (F) IgG clusters show no change in contribution with increasing gene expression levels. (G, H) Custom tracks are shown for G)Sfi1 (chr11:3073466–3095466) and H)Phactr3 (chr2:177908053–177930053), as identified by both MACS and SICER for genes differentially acetylated for H4K5 in FC over control. A gene contiguous to Sfi1 (Pisd-ps1/3) is highlighted in blue, the CDS is highlighted in green, and adjacent intergenic regions in pink. Neighboring genes (Eif4enif1, Drg1, Zfp931, Sycp2, Ppp1r3d, and 9030418K01Rik) are shown to emphasize H4K5ac enrichment in the vicinity of peak-called genes. Splice variants for Phactr3 (Refseq) are annotated below the track. Customized wig tracks were visualized in the UCSC Genome Browser.
Figure 5H4K5ac in the presence of TF binding sites relative to the TSS. (A) Percent of expressed genes acetylated for H4K5 by CFC with (red) or without (black) a TFBS at that position in the promoter, 2 kb upstream of the TSS in 5 bp increments. Lines are smoothed with a running median of width 10. Given that a gene can be acetylated at multiple sites in the promoter regardless of whether it is expressed or not, the percentage of acetylated genes at a specific position can be greater than 100%. Percent of unexpressed genes that are acetylated are plotted in gray. (B) Average read coverage of H4K5ac by CFC, ± 2 kb relative to the TSS, for all genes (black), genes with a TFBS present 500 bp (orange), 800 bp (green), or 1100 bp (turquoise) upstream of the TSS, and genes with no TFBS upstream of 100 bp of the TSS (blue). The relative contribution of gene clusters for (C) H4K5ac by CFC, (D) H4K12ac by CFC, and (E) mock IgG-IP with either no TFBS present in the promoter, or no TFBS, one TFBS, and multiple TFBS present upstream of 150 bp relative to the TSS. Clusters are defined in Figures 4A, 4C, and 4E, respectively.
GO enrichment analysis of MACS-identified genes differentially acetylated for H4K5 in FC and control in hippocampus
| GO:0045202 | Cellular component: synapse | FC | 5.78 | 8.01E-06 |
| GO:0000267 | Cellular component: cell fraction | FC | 3.48 | 7.33E-05 |
| GO:0005624 | Cellular component: membrane fraction | FC | 3.76 | 0.0001 |
| GO:0003008 | Biological process: system process | FC | 3.03 | 0.0002 |
| GO:0015491 | Molecular function: cation:cation antiporter activity | FC | 26.05 | 0.0002 |
| GO:0005626 | Cellular component: insoluble fraction | FC | 3.59 | 0.0002 |
| GO:0022892 | Molecular function: substrate-specific transporter activity | FC | 2.81 | 0.0004 |
| GO:0022891 | Molecular function: substrate-specific transmembrane transporter activity | FC | 2.93 | 0.0004 |
| GO:0014069 | Cellular component: postsynaptic density | FC | 11.65 | 0.0004 |
| GO:0007416 | Biological process: synapse assembly | FC | 18.89 | 0.0005 |
| GO:0006897 | Biological process: endocytosis | FC | 5.74 | 0.0006 |
| GO:0010324 | Biological process: membrane invagination | FC | 5.74 | 0.0006 |
| GO:0050885 | Biological process: neuromuscular process controlling balance | FC | 16.85 | 0.0007 |
| GO:0065008 | Biological process: regulation of biological quality | FC | 2.28 | 0.0008 |
| GO:0050877 | Biological process: neurological system process | FC | 3.08 | 0.0008 |
| GO:0022857 | Molecular function: transmembrane transporter activity | FC | 2.74 | 0.0008 |
| GO:0042592 | Biological process: homeostatic process | FC | 2.85 | 0.0009 |
| GO:0006810 | Biological process: transport | FC | 1.84 | 0.001 |
| GO:0043062 | Biological process: extracellular structure organization | FC | 6.49 | 0.001 |
| GO:0030424 | Cellular component: axon | FC | 6.38 | 0.0011 |
| GO:0005583 | Cellular component: fibrillar collagen | FC | 39.19 | 0.0011 |
| GO:0044456 | Cellular component: synapse part | FC | 4.92 | 0.0014 |
| GO:0005246 | Molecular function: calcium channel regulator activity | FC | 32.07 | 0.0017 |
| GO:0015075 | Molecular function: ion transmembrane transporter activity | FC | 2.73 | 0.0021 |
| GO:0015298 | Molecular function: solute:cation antiporter activity | FC | 11.8 | 0.0021 |
| GO:0005794 | Cellular component: Golgi apparatus | FC | 2.84 | 0.0025 |
| GO:0015385 | Molecular function: sodium:hydrogen antiporter activity | FC | 26.05 | 0.0026 |
| GO:0005451 | Molecular function: monovalent cation:hydrogen antiporter activity | FC | 26.05 | 0.0026 |
| GO:0005215 | Molecular function: transporter activity | FC | 2.24 | 0.0032 |
| GO:0005581 | Cellular component: collagen | FC | 19.59 | 0.0046 |
| GO:0000166 | Molecular function: nucleotide binding | Control | 4.43 | 5.04E-06 |
| GO:0032553 | Molecular function: ribonucleotide binding | Control | 4.31 | 7.57E-05 |
| GO:0032555 | Molecular function: purine ribonucleotide binding | Control | 4.31 | 7.57E-05 |
| GO:0017076 | Molecular function: purine nucleotide binding | Control | 4.15 | 0.0001 |
| GO:0005524 | Molecular function: ATP binding | Control | 4.76 | 0.0001 |
| GO:0032559 | Molecular function: adenyl ribonucleotide binding | Control | 4.71 | 0.0001 |
| GO:0005003 | Molecular function: ephrin receptor activity | Control | 112.59 | 0.0001 |
| GO:0050771 | Biological process: negative regulation of axonogenesis | Control | 90.12 | 0.0002 |
| GO:0021955 | Biological process: central nervous system neuron axonogenesis | Control | 96.56 | 0.0002 |
| GO:0001883 | Molecular function: purine nucleoside binding | Control | 4.47 | 0.0002 |
| GO:0030554 | Molecular function: adenyl nucleotide binding | Control | 4.49 | 0.0002 |
| GO:0001882 | Molecular function: nucleoside binding | Control | 4.45 | 0.0002 |
| GO:0031345 | Biological process: negative regulation of cell projection organization | Control | 71.15 | 0.0004 |
| GO:0010171 | Biological process: body morphogenesis | Control | 67.59 | 0.0004 |
| GO:0007492 | Biological process: endoderm development | Control | 46.61 | 0.0008 |
| GO:0021954 | Biological process: central nervous system neuron development | Control | 42.24 | 0.001 |
| GO:0050768 | Biological process: negative regulation of neurogenesis | Control | 39.76 | 0.0011 |
| GO:0010721 | Biological process: negative regulation of cell development | Control | 37.55 | 0.0013 |
| GO:0021953 | Biological process: central nervous system neuron differentiation | Control | 32.97 | 0.0017 |
| GO:0030027 | Cellular component: lamellipodium | Control | 26.13 | 0.0026 |
| GO:0031252 | Cellular component: cell leading edge | Control | 15.19 | 0.0076 |
| GO:0044428 | Cellular component: nuclear part | Control | 3.16 | 0.0353 |
| GO:0042995 | Cellular component: cell projection | Control | 3.99 | 0.0379 |
| GO:0031981 | Cellular component: nuclear lumen | Control | 3.91 | 0.0399 |
| GO:0005667 | Cellular component: transcription factor complex | Control | 6.25 | 0.0403 |
Summary of GO enrichment analysis of genes differentially acetylated for H4K5 in FC over control (FC) and control over FC (Control) by MACS and using Webgestalt GO analysis.
* Sorted according to treatment followed by P-value, using Benjamini-Hochberg correction for multiple comparisons.
KEGG pathways enriched in MACS-identified genes differentially acetylated for H4K5 in FC and control in hippocampus
| O-Glycan biosynthesis | FC | 64.22 | 0.0005 |
| Calcium signaling pathway | FC | 13.29 | 0.0015 |
| mTOR signaling pathway | FC | 32.11 | 0.0018 |
| Acute myeloid leukemia | FC | 29.48 | 0.0021 |
| Alzheimer's disease | FC | 10.18 | 0.0033 |
| Chronic myeloid leukemia | FC | 21.16 | 0.0041 |
| Cardiac muscle contraction | FC | 20.43 | 0.0044 |
| ErbB signaling pathway | FC | 19.34 | 0.0049 |
| Fc gamma R-mediated phagocytosis | FC | 17.13 | 0.0062 |
| Metabolic pathways | FC | 3.66 | 0.012 |
| Axon guidance | Control | 32.99 | 0.0001 |
| Calcium signaling pathway | Control | 22.59 | 0.0003 |
| Regulation of actin cytoskeleton | Control | 20.2 | 0.0005 |
| Long-term depression | Control | 39.19 | 0.0012 |
| Gap junction | Control | 32.52 | 0.0018 |
| Small cell lung cancer | Control | 32.52 | 0.0018 |
| GnRH signaling pathway | Control | 29.68 | 0.0021 |
| Melanogenesis | Control | 28.84 | 0.0022 |
| Vascular smooth muscle contraction | Control | 22.99 | 0.0035 |
| Focal adhesion | Control | 14.77 | 0.0082 |
Summary of KEGG pathway enrichment analysis of genes differentially acetylated for H4K5 in FC over control (FC) and control over FC (Control) by MACS using Webgestalt KEGG analysis.
* Sorted according to treatment followed by P-value, using Benjamini-Hochberg correction for multiple comparisons.
Real-time quantitative PCR validation of MACS-identified genes differentially acetylated for H4K5 in FC over control in the hippocampus [HIP] and cerebellum [CER]
| F-box and leucine-rich repeat protein 11 [Lysine (K)-specific demethylase 2A (Kdm2a)] | 4.31±1.40 | 0.05 | 1.04±0.05 | NS | |
| Ryanodine receptor 3 | 3.92±1.70 | 0.1 | 1.10±0.51 | NS | |
| A kinase (PRKA) anchor protein 6 | 3.77±0.71 | 0.01 | 3.94±1.37 | 0.05 | |
| ATPase, aminophospholipid transporter (APLT), class I, type 8A, member 1 | 3.35±0.46 | 0.01 | 0.96±0.23 | NS | |
| Neurexin I | 2.99±0.29 | 0.001 | 1.21±0.58 | NS | |
| Ring finger protein 220 | 2.98±1.84 | NS | 1.30±0.53 | NS | |
| Potassium voltage-gated channel, Shal-related family, member 2 | 2.94±0.36 | 0.001 | 0.46±0.11 | NS | |
| Glutamate receptor, ionotropic, delta 1 | 2.92±0.60 | 0.05 | 1.15±0.33 | NS | |
| Collagen, type II, alpha 1 | 2.35±0.42 | 0.01 | 1.01±0.21 | NS | |
| serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 9 | 1.90±0.90 | NS | 0.82±0.40 | NS | |
| Multiple EGF-like-domains 11 | 1.71±0.67 | NS | 1.01±0.33 | NS | |
| Neurotrophic tyrosine kinase, receptor, type 2 | 1.09±0.15 | NS | 1.32±0.20 | NS |
* Ranked according to fold-change in HIP.
Shown as fold-change over control ± SEM.
NS not significant.
Figure 6Model depicting gene priming through hyperacetylation of H4K5. Model depicting the potential role of H4K5ac preceding gene transcription. Sparse acetylation of H4K5 on nucleosomes associated with the promoter region is not sufficient for the recruitment of TFs necessary to initiate transcription. In contrast, hyperacetylation of H4K5 on nucleosomes along the promoter opens chromatin to allow access to large stretches of DNA for the recruitment of TFs proximal to the TSS. Upon binding, TFs may temporarily displace nucleosomes carrying the H4K5ac mark. In the CDS, H4K5ac and H4K12ac proximal to the TSS are necessary for transcriptional elongation by RNA polymerase. H4K5ac may be required throughout the gene body for full extension and/or transcription of splice variants such as Phactr3, whereas H4K12ac may only be needed in the CDS proximal to the TSS. This model proposes that hyperacetylation of H4K5 is needed at the promoter to prime genes for transcriptional initiation but also in the CDS for transcriptional elongation.